{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:20:27Z","timestamp":1787642427487,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","award":["2024JJ6289, 2025JJ80824"],"award-info":[{"award-number":["2024JJ6289, 2025JJ80824"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Climb Plan of Hunan Cancer Hospital","award":["ZX2021005, QH2023006 and QH2023011"],"award-info":[{"award-number":["ZX2021005, QH2023006 and QH2023011"]}]},{"name":"High-Level Talent Support Program of Hunan Cancer Hospital","award":["20250731-1050"],"award-info":[{"award-number":["20250731-1050"]}]},{"DOI":"10.13039\/501100004241","name":"China Primary Health Care Foundation","doi-asserted-by":"publisher","award":["cphcf-2023-056"],"award-info":[{"award-number":["cphcf-2023-056"]}],"id":[{"id":"10.13039\/501100004241","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Science and Technology Innovation Medical Development Foundation","award":["KC2023-JX-0082-05"],"award-info":[{"award-number":["KC2023-JX-0082-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10549-026-08019-y","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:52:17Z","timestamp":1785502337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine learning and cox model\u2013based prediction of CDK4\/6 inhibitor outcomes in HR+\/HER2\u2009\u2212\u2009metastatic breast cancer: a multicenter real-world study"],"prefix":"10.1007","volume":"218","author":[{"given":"Binliang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijuan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaili","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiantao","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huichong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"6","key":"8019_CR1","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN et al (2024) Breast cancer statistics 2024. CA Cancer J Clin 74(6):477\u2013495","journal-title":"CA Cancer J Clin"},{"key":"8019_CR2","doi-asserted-by":"publisher","first-page":"175883592413020","DOI":"10.1177\/17588359241302018","volume":"16","author":"Y Chen","year":"2024","unstructured":"Chen Y et al (2024) Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+\/HER2 \u2013 metastatic breast cancer patients: a multicenter study (YOUNGBC-28). Therapeutic Adv Med Oncol 16:17588359241302018","journal-title":"Therapeutic Adv Med Oncol"},{"key":"8019_CR3","doi-asserted-by":"crossref","unstructured":"Liu B et al (2024) Beyond clinical trials: CDK4\/6 inhibitor efficacy predictors and nomogram model from real-world evidence in metastatic breast cancer. Cancer Innov 3(6)","DOI":"10.1002\/cai2.143"},{"issue":"20","key":"8019_CR4","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS et al (2016) Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 375(20):1925\u20131936","journal-title":"N Engl J Med"},{"issue":"11","key":"8019_CR5","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1093\/annonc\/mdz215","volume":"30","author":"GN Hortobagyi","year":"2019","unstructured":"Hortobagyi GN et al (2019) Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 30(11):1842","journal-title":"Ann Oncol"},{"issue":"32","key":"8019_CR6","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP et al (2017) MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35(32):3638\u20133646","journal-title":"J Clin Oncol"},{"issue":"6","key":"8019_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"P Zhang","year":"2023","unstructured":"Zhang P et al (2023) Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 24(6):646\u2013657","journal-title":"Lancet Oncol"},{"issue":"10","key":"8019_CR8","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","volume":"386","author":"GN Hortobagyi","year":"2022","unstructured":"Hortobagyi GN et al (2022) Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 386(10):942\u2013950","journal-title":"N Engl J Med"},{"key":"8019_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.breast.2020.10.005","volume":"54","author":"A Batra","year":"2020","unstructured":"Batra A, Kong S, Cheung WY (2020) Eligibility of real-world patients with metastatic breast cancer for clinical trials. Breast 54:171\u2013178","journal-title":"Breast"},{"key":"8019_CR10","doi-asserted-by":"publisher","first-page":"104665","DOI":"10.1016\/j.breast.2025.104665","volume":"85","author":"R Duchnowska","year":"2026","unstructured":"Duchnowska R et al (2026) Real-world outcomes with palbociclib, ribociclib, and abemaciclib plus endocrine therapy in HR+\/HER2 \u2013 advanced breast cancer: A multicenter retrospective study. Breast 85:104665","journal-title":"Breast"},{"issue":"17","key":"8019_CR11","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.3390\/cancers17172788","volume":"17","author":"MS Abbasi","year":"2025","unstructured":"Abbasi MS et al (2025) Efficacy and Predictability of Cyclin-Dependent Kinase 4\/6 Inhibitors in HER2-Positive Breast Cancer. Cancers 17(17):2788","journal-title":"Cancers"},{"issue":"4","key":"8019_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s12282-025-01713-7","volume":"32","author":"T Yoshinami","year":"2025","unstructured":"Yoshinami T et al (2025) Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4\/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Breast Cancer 32(4):841\u2013856","journal-title":"Breast Cancer"},{"issue":"7","key":"8019_CR13","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.3390\/ijms26073357","volume":"26","author":"I Stanciu","year":"2025","unstructured":"Stanciu I et al (2025) Impact of Patient Profile on CDK4\/6 Inhibitor Therapy Outcomes: A Real-World Data Analysis. Int J Mol Sci 26(7):3357","journal-title":"Int J Mol Sci"},{"key":"8019_CR14","doi-asserted-by":"crossref","unstructured":"Giugliano F et al (2025) Overcoming resistance to CDK4\/6 inhibitors in hormone receptor positive, HER2 negative breast cancer: Innovative combinations and emerging strategies. Cancer Treat Rev 102980","DOI":"10.1016\/j.ctrv.2025.102980"},{"issue":"1","key":"8019_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","volume":"162","author":"GS Collins","year":"2015","unstructured":"Collins GS et al (2015) Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 162(1):55\u201363","journal-title":"Ann Intern Med"},{"key":"8019_CR16","doi-asserted-by":"crossref","unstructured":"Moncada-Torres A et al (2021) Explainable machine learning can outperform Cox regression predictions and provide insights in breast cancer survival. Sci Rep 11(1)","DOI":"10.1038\/s41598-021-86327-7"},{"key":"8019_CR17","doi-asserted-by":"crossref","unstructured":"Ishwaran H et al (2008) Random survival forests. Annals Appl Stat 2(3)","DOI":"10.1214\/08-AOAS169"},{"key":"8019_CR18","doi-asserted-by":"publisher","first-page":"873595","DOI":"10.1155\/2013\/873595","volume":"2013","author":"Y Chen","year":"2013","unstructured":"Chen Y et al (2013) A gradient boosting algorithm for survival analysis via direct optimization of concordance index. Comput Math Methods Med 2013:873595","journal-title":"Comput Math Methods Med"},{"key":"8019_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tbcr-25-37","volume":"7","author":"B Liu","year":"2026","unstructured":"Liu B et al (2026) Real-world efficacy and prognostic factors of CDK4\/6 inhibitors in HR+\/HER2 \u2013 metastatic breast cancer: a multicenter retrospective study from the Dongting Lake region of China. Translational Breast Cancer Res 7:2\u20132","journal-title":"Translational Breast Cancer Res"},{"issue":"20","key":"8019_CR20","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC et al (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 36(20):2105\u20132122","journal-title":"J Clin Oncol"},{"issue":"2","key":"8019_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"2","key":"8019_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s10549-024-07580-8","volume":"210","author":"C Doyle","year":"2025","unstructured":"Doyle C et al (2025) A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy \u00b1 targeted therapy in HR + HER2-negative advanced breast cancer. Breast Cancer Res Treat 210(2):425\u2013438","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"8019_CR23","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","volume":"36","author":"L Provenzano","year":"2025","unstructured":"Provenzano L et al (2025) Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study. Ann Oncol 36(7):762\u2013774","journal-title":"Ann Oncol"},{"key":"8019_CR24","doi-asserted-by":"crossref","unstructured":"Yang B et al (2025) Safety and quality of life of CDK4\/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China. BMC Cancer 25(1)","DOI":"10.1186\/s12885-025-14223-8"},{"key":"8019_CR25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.breast.2016.10.021","volume":"31","author":"M Bonotto","year":"2017","unstructured":"Bonotto M et al (2017) Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. Breast 31:114\u2013120","journal-title":"Breast"},{"key":"8019_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.breast.2021.02.015","volume":"57","author":"D Basile","year":"2021","unstructured":"Basile D et al (2021) First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Breast 57:104\u2013112","journal-title":"Breast"},{"key":"8019_CR27","doi-asserted-by":"crossref","unstructured":"Miglietta F et al (2025) The evolving landscape of hormone receptor-positive\/HER2-negative metastatic breast cancer (EVOLVE): an Italian Delphi consensus report. Crit Rev Oncol\/Hematol 104793","DOI":"10.1016\/j.critrevonc.2025.104793"},{"issue":"4","key":"8019_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425\u2013439","journal-title":"Lancet Oncol"},{"key":"8019_CR29","doi-asserted-by":"publisher","first-page":"115113","DOI":"10.1016\/j.ejca.2024.115113","volume":"213","author":"C Molinelli","year":"2024","unstructured":"Molinelli C et al (2024) The journey of patients affected by metastatic hormone receptor-positive\/HER2-negative breast cancer from CDK 4\/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14\/BIOMETA study. Eur J Cancer 213:115113","journal-title":"Eur J Cancer"},{"key":"8019_CR30","doi-asserted-by":"publisher","first-page":"e2200531","DOI":"10.1200\/PO.22.00531","volume":"7","author":"L Gerratana","year":"2023","unstructured":"Gerratana L et al (2023) Cyclin-Dependent Kinase 4\/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO Precis Oncol 7:e2200531","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"8019_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000527917","volume":"18","author":"C M\u00fcller","year":"2023","unstructured":"M\u00fcller C et al (2023) CDK4\/6 Inhibitors in Advanced HR+\/HER2 \u2013 Breast Cancer: A Multicenter Real-World Data Analysis. Breast Care 18(1):31\u201341","journal-title":"Breast Care"},{"issue":"1","key":"8019_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10238-024-01458-1","volume":"24","author":"B Chen","year":"2024","unstructured":"Chen B et al (2024) Real-world experience with CDK4\/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population. Clin Experimental Med 24(1):185","journal-title":"Clin Experimental Med"},{"key":"8019_CR33","doi-asserted-by":"publisher","first-page":"104715","DOI":"10.1016\/j.breast.2026.104715","volume":"86","author":"S Pannunzio","year":"2026","unstructured":"Pannunzio S et al (2026) Predicting progression-free survival in hormone-receptor positive (HR+\/HER2-) metastatic breast cancer (MBC) treated with CDK4\/6 inhibitors: A machine learning approach. Breast 86:104715","journal-title":"Breast"},{"issue":"1","key":"8019_CR34","doi-asserted-by":"publisher","first-page":"5597051","DOI":"10.1155\/ijbc\/5597051","volume":"2025","author":"T Susiriwatananont","year":"2025","unstructured":"Susiriwatananont T et al (2025) Clinical Outcomes of HER2-Low Versus HER2\u2010Zero in HR\u2010Positive Metastatic Breast Cancer Treated With Endocrine Therapy With or Without CDK4\/6 Inhibitors: A Multicenter Retrospective Study. Int J Breast Cancer 2025(1):5597051","journal-title":"Int J Breast Cancer"},{"issue":"4","key":"8019_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cpt.2023.07.004","volume":"1","author":"L Ning","year":"2023","unstructured":"Ning L et al (2023) Survival nomogram for patients with de novo metastatic breast cancer based on the SEER database and an external validation cohort. Cancer Pathogenesis Therapy 1(4):253\u2013261","journal-title":"Cancer Pathogenesis Therapy"},{"key":"8019_CR36","doi-asserted-by":"crossref","unstructured":"Liu B et al (2020) Development and validation of a new clinical prediction model of catheter-related thrombosis based on vascular ultrasound diagnosis in cancer patients. Front Cardiovasc Med 7","DOI":"10.3389\/fcvm.2020.571227"},{"issue":"1","key":"8019_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12874-025-02694-z","volume":"25","author":"Y Huang","year":"2025","unstructured":"Huang Y et al (2025) Comparison of machine learning methods versus traditional Cox regression for survival prediction in cancer using real-world data: a systematic literature review and meta-analysis. BMC Med Res Methodol 25(1):243","journal-title":"BMC Med Res Methodol"},{"key":"8019_CR38","doi-asserted-by":"publisher","first-page":"111176","DOI":"10.1016\/j.compbiomed.2025.111176","volume":"198","author":"G Birolo","year":"2025","unstructured":"Birolo G et al (2025) Beyond Cox models: Assessing the performance of machine-learning methods in non-proportional hazards and non-linear survival analysis. Comput Biol Med 198:111176","journal-title":"Comput Biol Med"},{"issue":"2","key":"8019_CR39","doi-asserted-by":"publisher","first-page":"e33440","DOI":"10.2196\/33440","volume":"10","author":"J Xiao","year":"2022","unstructured":"Xiao J et al (2022) The Application and Comparison of Machine Learning Models for the Prediction of Breast Cancer Prognosis: Retrospective Cohort Study. JMIR Med Inf 10(2):e33440","journal-title":"JMIR Med Inf"},{"issue":"11","key":"8019_CR40","doi-asserted-by":"publisher","first-page":"e70056","DOI":"10.1111\/cts.70056","volume":"17","author":"AV Ponce-Bobadilla","year":"2024","unstructured":"Ponce-Bobadilla AV et al (2024) Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development. Clin Transl Sci 17(11):e70056","journal-title":"Clin Transl Sci"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08019-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08019-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08019-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:49:10Z","timestamp":1787640550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08019-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["8019"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08019-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The current study protocol was registered at ClinicalTrials.gov (NCT06033287; registered on September 13, 2023) and conducted in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee of Hunan Cancer Hospital. As this was a retrospective study based on anonymized data, the requirement for written informed consent was waived by the Ethics Committee of Hunan Cancer Hospital.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27"}}